Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Allarity Therapeutics Inc (ALLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: ALLR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.25
1 Year Target Price $9.25
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.29% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.22M USD | Price to earnings Ratio 0.27 | 1Y Target Price 9.25 |
Price to earnings Ratio 0.27 | 1Y Target Price 9.25 | ||
Volume (30-day avg) 1 | Beta 0.22 | 52 Weeks Range 0.61 - 2.25 | Updated Date 10/14/2025 |
52 Weeks Range 0.61 - 2.25 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.03% | Return on Equity (TTM) -150.58% |
Valuation
Trailing PE 0.27 | Forward PE - | Enterprise Value 7103009 | Price to Sales(TTM) - |
Enterprise Value 7103009 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.08 | Shares Outstanding 14524080 | Shares Floating 14594636 |
Shares Outstanding 14524080 | Shares Floating 14594636 | ||
Percent Insiders 2.9 | Percent Institutions 1.96 |
Upturn AI SWOT
Allarity Therapeutics Inc
Company Overview
History and Background
Allarity Therapeutics Inc. (ALLR) is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments by utilizing its proprietary Drug Response Predictor (DRPu00ae) technology to select patients most likely to respond to its drug candidates. Founded to improve cancer treatment outcomes.
Core Business Areas
- Oncology Drug Development: Focused on developing and commercializing cancer therapeutics, with a primary emphasis on personalized medicine through its DRP technology.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. Organizational structure typically consists of executive leadership, research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- IXEMPRA: A product the company acquired with approved and marketed indication.
- Stenoparib: A PARP inhibitor under development for ovarian cancer and other indications. Currently in clinical trials. No significant market share yet. Competitors include AstraZeneca (AZN) with Lynparza and GSK (GSK) with Zejula.
Market Dynamics
Industry Overview
The oncology market is large and competitive, driven by increasing cancer incidence and advancements in treatment options. Personalized medicine is a growing trend.
Positioning
Allarity aims to differentiate itself through its DRP technology, which is intended to improve patient selection and treatment outcomes. It is a smaller player compared to larger pharmaceutical companies.
Total Addressable Market (TAM)
The global oncology market is valued in the hundreds of billions of dollars. Allarity's DRP-driven approach allows for a focused TAM targeting patient populations more likely to respond, but actual market penetration depends on clinical trial success and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary DRPu00ae technology
- Personalized medicine approach
- Potential for improved patient outcomes
- Clinical-stage pipeline
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
- Dependence on DRP technology validation
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of DRPu00ae technology to other cancer types
- Positive clinical trial results
- Regulatory approvals
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- AZN
- GSK
- MRK
Competitive Landscape
Allarity faces intense competition from larger, well-established pharmaceutical companies. Its DRP technology is its key differentiator, but success depends on proving its value in clinical trials and securing partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on clinical trial progress and potential partnerships. This data is unavailable within the context window.
Future Projections: Future growth depends on the success of stenoparib and other pipeline assets. This data is unavailable within the context window.
Recent Initiatives: Recent initiatives include advancing clinical trials for stenoparib, seeking partnerships, and further validating DRP technology.
Summary
Allarity Therapeutics is a clinical-stage company focused on personalized cancer treatments using its DRP technology. Its success hinges on positive clinical trial results and strategic partnerships. The company faces significant competition and financial constraints, but the personalized medicine approach offers potential for differentiation. Allarity needs to demonstrate the clinical and commercial value of its DRP technology and pipeline assets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allarity Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-12-21 | Founder, CEO & Director Mr. Thomas H. Jensen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.allarity.com |
Full time employees 6 | Website https://www.allarity.com | ||
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.